Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: The Japan Statin Treatment Against Recurrent Stroke (J-STARS)

International Journal of Stroke

Volumn 9, Issue 2, 2014, Pages 232-239

  Nagai, Yoji ^a   Kohriyama, Tatsuo ^b   Origasa, Hideki ^c   Minematsu, Kazuo ^d   Yokota, Chiaki ^d   Uchiyama, Shinichiro ^e   Ibayashi, Setsuro ^f   Terayama, Yasuo ^g   Takagi, Makoto ^h   Kitagawa, Kazuo ⁱ   Nomura, Eiichi ^b   Hosomi, Naohisa ^b   Ohtsuki, Toshiho ^b   Yamawaki, Takemori ^b   Matsubara, Yoshihiro ^a   Nakamura, Masakazu ^d   Yamasaki, Yoshimitsu ⁱ   Mori, Etsuro ^j   Fukushima, Masanori ^a   Kobayashi, Shotai ^k   Shinohara, Yukito ^l   Yamaguchi, Takenori ^d   Matsumoto, Masayasu ^b   more..

^a Translational Research Informatics Center Foundation for Biomedical Research and Innovation   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^e TOKYO WOMEN S MEDICAL UNIVERSITY MEDICAL CENTER EAST   (Japan)

^f Seiai Rehabilitation Hospital   (Japan)

^g IWATE MEDICAL UNIVERSITY   (Japan)

^h SAISEIKAI CENTRAL HOSPITAL   (Japan)

ⁱ OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^l Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

more..

Author keywords

Recurrence; Secondary prevention; Statins; Stroke

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; ARTERY PERFORATION; ARTICLE; ATHEROTHROMBOTIC INFARCTION; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COGNITION; CONTROLLED STUDY; DISABILITY; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; INFARCTION OF UNDETERMINED ETIOLOGY; JAPANESE; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SAMPLE SIZE; STROKE PATIENT; TREATMENT OUTCOME;

RECURRENCE; SECONDARY PREVENTION; STATINS; STROKE;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ENZYME INHIBITORS; FEMALE; HUMANS; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTPATIENTS; PRAVASTATIN; RECURRENCE; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; STROKE; TREATMENT OUTCOME;

EID: 84892810044     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12099     Document Type: Article

References (31)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
2. Psaty BM, Lumley T, Furberg CD etal. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289:2534-2544.
3. Pearson TA. Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins. Am J Cardiol 1998; 82:28S-30S.
4. Plehn JF, Davis BR, Sacks FM etal. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 1999; 99:216-223.
5. White HD, Simes RJ, Anderson NE etal. Pravastatin therapy and the risk of stroke. N Engl J Med 2000; 343:317-326.
6. Sever PS, Dahlof B, Poulter NR etal. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158.
7. Kushiro T, Mizuno K, Nakaya N etal. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension 2009; 53:135-141.
8. Amarenco P, Bogousslavsky J, Callahan A 3rd etal. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-559.
9. Manktelow BN, Potter JF. Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev 2009; (3):CD002091.
10. Henyan NN, Riche DM, East HE, Gann PN. Impact of statins on risk of stroke: a meta-analysis. Ann Pharmacother 2007; 41:1937-1945.
11. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8:453-463.
12. Paciaroni M, Bogousslavsky J. Statins and stroke prevention. Expert Rev Cardiovasc Ther 2009; 7:1231-1243.
13. Sadowitz B, Maier KG, Gahtan V. Basic science review: statin therapy - part I: the pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg 2010; 44:241-251.
14. Willey JZ, Elkind MS. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol 2010; 67:1062-1067.
15. Zhou Q, Liao JK. Pleiotropic effects of statins. - Basic research and clinical perspectives. Circ J 2010; 74:818-826.
16. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100:230-235.
17. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64-70.
18. Ridker PM, Danielson E, Fonseca FA etal. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
19. Crouse JR 3rd, Raichlen JS, Riley WA etal. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297:1344-1353.
20. Bedi US, Singh M, Singh PP etal. Effects of statins on progression of carotid atherosclerosis as measured by carotid intimal - medial thickness: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 2010; 15:268-273.
21. Liu M, Wang F, Wang Y, Jin R. Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation. Cardiovasc Drugs Ther 2009; 23:369-376.
22. Reriani MK, Dunlay SM, Gupta B etal. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J Cardiovasc Prev Rehabil 2011; 18:704-716.
23. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2004; 117:596-606.
24. Adams HP Jr, Bendixen BH, Kappelle LJ etal. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24:35-41.
25. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 1990; 21:637-676.
26. Yokota C, Minematsu K, Hasegawa Y, Yamaguchi T. Long-term prognosis, by stroke subtypes, after a first-ever stroke: a hospital-based study over a 20-year period. Cerebrovasc Dis 2004; 18:111-116.
27. Peto R, Pike MC, Armitage P etal. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34:585-612.
28. Uchiyama S, Nakaya N, Mizuno K etal. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. J Neurol Sci 2009; 284:72-76.
29. Amarenco P, Benavente O, Goldstein LB etal. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 2009; 40:1405-1409.
30. Turin TC, Kita Y, Rumana N etal. Ischemic stroke subtypes in a Japanese population: Takashima Stroke Registry, 1988-2004. Stroke 2010; 41:1871-1876.
31. Vaughan CJ. Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am J Cardiol 2003; 91:23B-29.